On July 30, SBP GROUP declined 3.06% in regular trading, trading at 5.09 HKD/share with turnover of approximately 38.48 million HKD. The stock weakened amid broad-based selling pressure across the pharmaceutical sector.

Within the Pharmaceuticals sector, peers declined in tandem: CSPC Pharma fell 2.63%, ASYMCHEM dropped 2.75%, HANSOH Pharma lost 1.67%, and HENGRUI Pharma slipped 0.34%. The sector-wide downturn weighed broadly on constituent stocks. Additionally, Nomura recently trimmed its target price for SBP GROUP from HK$8.67 to HK$8.26 while maintaining a Buy rating, with the consensus analyst mean target at HK$7.97 — still well above the current trading level.

Recent catalysts include the company establishing a 51%-owned joint venture with Indonesia's Tempo Scan on July 27 to deepen Southeast Asian market penetration, and obtaining clinical trial approval for its IM-101 hepatitis B drug on July 23.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)